Trials / Completed
CompletedNCT00828191
Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)
Efficacy and Tolerability of Subcutaneous Progesterone (IBSA) Versus Vaginal Progesterone for Luteal Phase Support in Patients Undergoing In Vitro Fertilization (IVF)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 800 (actual)
- Sponsor
- IBSA Institut Biochimique SA · Industry
- Sex
- Female
- Age
- 18 Years – 42 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, open, randomized, parallel, multicenter, two-arm trial to evaluate the efficacy and tolerability of a new progesterone formulation to be used for luteal support in IVF (Progesterone-IBSA) administered subcutaneously at a daily dose of 25 mg versus Progesterone tablets administered intravaginally at 100 mg twice daily for a total dose of 200 mg.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Progesterone | 25 mg, once a day, SC |
| DRUG | Progesterone | 100 mg, twice a day, vaginally |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2011-07-01
- Completion
- 2012-02-01
- First posted
- 2009-01-23
- Last updated
- 2013-01-31
- Results posted
- 2012-12-26
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00828191. Inclusion in this directory is not an endorsement.